Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy: Association with insulin resistance  by Shigematsu, Yuji et al.
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Summary
Background:  We  undertook  a  cross-sectional  study  to  test  the  hypothesis  that  patients  with
hypertrophic  cardiomyopathy  (HCM)  who  have  impaired  left  ventricular  (LV)  diastolic  func-
tion are  insulin  resistant.  We  also  evaluated  the  relation  between  the  development  of  atrial
ﬁbrillation  (AF)  and  insulin  resistance  (IR)  in  patients  with  HCM.
Methods  and  results:  Eighty-eight  patients  with  HCM  (71  men,  17  women)  were  enrolled  in
the study.  IR  was  estimated  using  the  homeostasis  model  assessment  (HOMA)  index.  Echocar-
diographically  determined  left  atrial  (LA)  dimension  was  measured  as  a  marker  of  LA  size.  The
ratio of  trasmitral  early  LV  ﬁlling  velocity  to  early  diastolic  mitral  annulus  velocity  (E/e′)  was  also
measured as  a  marker  of  LV  diastolic  function.  Twenty-seven  patients  (31%)  had  IR.  Multivariate
logistic  regression  analyses  showed  that  independent  determinants  of  AF  were  increased  LA  size
[odds ratio  (OR)  3.5,  95%  conﬁdence  interval  (CI)  1.2—9.8]  and  impaired  LV  diastolic  function  [OR
4.6, 95%  CI  1.6—12.8].  The  strongest  determinant  of  LA  size  was  the  HOMA  index  (p  =  0.0005).
Similarly, the  HOMA  index  (p  =  0.0019)  was  an  independent  determinant  of  LV  diastolic  function.
∗ Corresponding author. Tel.: +81 89 960 5410; fax: +81 89 960 5410.
E-mail address: yujis@m.ehime-u.ac.jp (Y. Shigematsu).
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Conclusion:  IR  is  highly  prevalent  among  non-diabetic  patients  with  HCM.  A  possible  mechanism
by which  IR  affects  the  development  of  AF  is  mediated  through  its  association  with  increased
LA size  or  impaired  LV  diastolic  function.  IR  may  be  an  important  underlying  mechanism  for  the
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reactive  insulin  (FIRI)  and  fasting  plasma  glucose  (FPG)
and  the  previously  validated  homeostasis  model  assess-
ment  (HOMA)  [21], thus:  HOMA  index  =  FIRI  (pmol/L)  ×  FPGgenesis of  AF  in  HCM.
©  2011  Japanese  College  of  C
Introduction
Atrial  ﬁbrillation  (AF)  is  a  particularly  important  arrhythmia
in  hypertrophic  cardiomyopathy  (HCM)  [1—3]. AF  devel-
ops  in  a  substantial  proportion  of  adult  patients  with  HCM
[1—4]  and  is  associated  with  increased  systemic  throm-
boembolism,  heart  failure,  and  death  [5,6]. In  addition,  AF
contributes  to  a  poor  prognosis  because  of  deterioration  in
cardiac  function  [7].  However,  it  is  unclear  how  AF  develops
in  patients  with  HCM.  A  number  of  mechanisms  have  been
proposed,  including  neurohormonal  alterations,  oxidative
stress,  ﬁbrosis,  and  maladaptive  hemodynamic  and  baro-
dynamic  changes  with  resulting  abnormalities  in  electrical
conduction  [8].
Insulin  resistance  has  been  associated  with  chronic  heart
failure  independently  of  its  etiology  [9,10]. HCM  is  function-
ally  characterized  by  impaired  left  ventricular  (LV)  diastolic
function  [11,12]  and  we  have  reported  that  patients  with
HCM  without  apparent  diabetes  mellitus  or  hypertension
have  insulin  resistance  [13]. The  metabolic  syndrome  con-
sists  of  a  cluster  of  atherosclerotic  risk  factors,  including
insulin  resistance,  obesity,  hypertension,  and  dyslipidemia.
Many  atherosclerotic  risk  factors  are  implicated  in  the
pathogenesis  of  AF  [14,15].  One  recent  study  in  Japan  has
shown  the  relation  between  metabolic  syndrome  and  the
development  of  AF  [16]. Although  insulin  resistance  plays
an  important  role  in  the  pathogenesis  of  metabolic  syn-
drome,  the  precise  relation  between  insulin  resistance  and
the  development  of  AF  has  not  been  assessed  in  patients
with  HCM.
We  therefore  undertook  a  cross-sectional  study  to  test
the  hypothesis  that  patients  with  HCM  who  have  impaired
diastolic  function  are  insulin  resistant.  We  have  also  evalu-
ated  the  relation  between  the  development  of  AF  and  insulin
resistance  in  patients  with  HCM.
Methods
Study  patients
Eighty-eight  patients  with  HCM  (71  men,  17  women;  mean
age:  65  ±  11  years)  participated  in  this  study.  They  had
normal  ﬁndings  on  chemical  screening  battery  and  were  non-
diabetic  by  the  criteria  of  the  American  Diabetes  Association
[17].  Coronary  angiographic  studies  were  performed  in  all
study  patients  and  none  of  them  had  coronary  artery  dis-
ease.  The  study  was  carried  out  in  accordance  with  the
Declaration  of  Helsinki  (1989)  of  the  World  Medical  Asso-
ciation.  All  patients  gave  their  informed  consent  prior  to
participation  in  the  study.Deﬁnitions  of  HCM  and  AF
HCM  was  deﬁned  as  the  presence  of  a  hypertrophied,
non-dilated  ventricle  in  the  absence  of  underlying  car-
(
o
m
dology.  Published  by  Elsevier  Ltd.  All  rights  reserved.
iac  or  systemic  secondary  causes  and  was  based  on  World
ealth  Organization/International  Society  and  Federation
f  Cardiology  deﬁnition  of  cardiomyopathies  [18]. Patients
ith  HCM  were  subdivided  into  2  groups:  hypertrophic
bstructive  cardiomyopathy  (HOCM)  and  hypertrophic  non-
bstructive  cardiomyopathy  (HNCM).  HOCM  was  diagnosed
hen  a  patient  had  a  LV  pressure  gradient  greater  than
0  mmHg  without  provocation  in  the  LV  outﬂow  tract  and/or
id-ventricle  [19].
Documentation  of  AF  was  based  on  electrocardiography
ecordings  obtained  either  after  acute  onset  of  symptoms  or
ortuitously  during  routine  medical  examination  in  asymp-
omatic  patients.  AF  was  deﬁned  as  paroxysmal  when  it  was
ither  self-terminating  or  successfully  cardioverted  to  sinus
hythm;  AF  was  considered  chronic  when  it  became  estab-
ished.
hysical  examinations
hysical  examinations  in  study  patients  were  supervised  by
he  nursing  staff.  Weight  and  height  were  measured  while
he  subjects  were  fasting  overnight  and  wearing  only  under-
ear.  Body  mass  index  (BMI)  was  calculated  as  weight  (kg)
ivided  by  height  (m)2.  Blood  pressure  (BP)  was  measured  in
riplicate  by  a  single  physician  with  an  appropriate  arm  cuff
nd  a  mercury  sphygmomanometer  after  5  minutes’  rest  in
he  sitting  position.  The  arithmetic  mean  of  the  last  two
easurements  was  calculated.  Korotkoff  phase  V  was  taken
or  diastolic  blood  pressure.
ssessments  of  biochemical  parameters  and
atriuretic peptides
enous  blood  was  taken  in  the  morning  after  overnight  fast-
ng  in  the  outpatient  clinic.  Plasma  glucose  was  immediately
etermined  by  the  glucose  oxidase  method.  Plasma  insulin
as  determined  in  duplicate  by  high  speciﬁc  and  sensi-
ive  immunoradiometric  assay  (Abbott  Japan,  Tokyo,  Japan;
ntra-assay  coefﬁcient  of  variation  [CV]  1.6%,  interassay
V  2.2%).  Serum  concentrations  of  low-density  lipoprotein
holesterol  (LDL-C),  high-density  lipoprotein  cholesterol
HDL-C),  and  triglycerides  (TG)  were  assessed  by  standard
nzymatic  methods.  Plasma  levels  of  atrial  and  brain  natri-
retic  peptides  (ANP  and  BNP)  were  also  measured  in  all
atients,  as  previously  reported  [20].
Insulin  resistance  was  assessed  from  fasting  immuno-mmol/L)/161.  On  the  basis  of  FPG  upper  limit  of  normal
f  6.1  mmol/L  and  our  laboratory’s  upper  limit  of  nor-
al  for  FIRI  of  71.0  pmol/L,  a  HOMA  index  of  2.69  was
etermined  as  the  upper  limit  of  normal.  An  individual
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ith  the  HOMA  index  ≥2.7  was  considered  to  have  insulin
esistance  [10].
chocardiographic  measurements
wo-dimensionally  guided  M-mode  echocardiography  was
erformed  by  standard  methods,  as  previously  outlined
5,13,22],  using  a  Vivid  7  Dimension  ultrasound  machine
GE  Healthcare,  Milwaukee,  WI,  USA)  with  an  M4S  probe.
chocardiographic  examinations  were  performed  and  inter-
reted  by  the  same  cardiologist,  who  was  unaware  of  the
atient’s  data.  Left  atrial  (LA)  dimension  was  measured  at
nd-systole,  according  to  the  American  Society  of  Echocar-
iography  guidelines  [23]. Interventricular  septal  thickness
nd  LV  posterior  wall  thickness  were  also  measured  in  end-
iastole  at  the  level  of  the  mitral  valve.  LV  end  diastolic  and
nd  systolic  volumes  (EDV  and  ESV),  and  ejection  fraction
EF)  were  estimated  by  Simpson’s  rule  from  two-dimensional
pical  chamber  view.
LV  pressure  gradient  was  measured  from  continuous-wave
oppler  imaging  of  the  LV  outﬂow  tract  and/or  mid-ventricle
19,24].  Early  diastolic  mitral  annular  velocity  at  the  septal
nd  lateral  side  (e′)  was  obtained  by  tissue  Doppler  imaging,
hich  reﬂects  the  time  constant  of  isovolumic  LV  relaxation
tau)  [25]. The  combined  assessment  of  peak  early  diastolic
ransmitral  ﬂow  velocity  (E)  and  e′,  E/e′, was  used  as  a
urrogate  of  LV  ﬁlling  pressure  [26].
ubgroup  analyses
n  the  basis  of  cardiac  rhythm,  patients  with  HCM  were  dis-
ributed  into  the  following  three  subgroups:  HCM  with  sinus
hythm  group  (n  =  54),  HCM  with  chronic  AF  group  (n  =  22),
nd  HCM  with  paroxysmal  AF  group  (n  =  12).  To  investigate
he  determinants  of  AF,  patients  with  HCM  were  distributed
nto  two  subgroups:  HCM  with  sinus  rhythm  (n  =  54)  and  HCM
ith  chronic  AF  or  paroxysmal  AF  (n  =  34),  and  subgroup
nalyses  were  performed.
tatistical  analysis
ll  values  are  expressed  as  mean  ±  SD.  One-way  analysis  of
ariance  (ANOVA)  was  used  to  evaluate  difference  among
roups,  with  Scheffe’s  correction  for  multiple  comparisons.
ategorical  variables  were  compared  with  Fisher’s  exact  and
hi-square  tests.  Univariate  and  multivariate  logistic  regres-
ion  analyses  were  used  to  examine  the  effects  of  age,  sex,
MI,  insulin  resistance,  and  echocardiographic  variables  on
he  risk  of  AF.  These  results  were  expressed  as  odds  ratios
ORs)  and  95%  conﬁdence  intervals  (CIs).
Correlation  coefﬁcients  were  calculated  according  to
earson’s  method.  Multiple  regression  analysis  was  also
erformed  to  select  appropriate  independent  variables  pro-
ucing  the  highest  partial  correlation  with  LA  size  or  LV
iastolic  function.  Probability  values  <0.05  were  considered
tatistically  signiﬁcant  in  all  analyses.
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esults
he  clinical  characteristics  of  patients  with  HCM  are  pre-
ented  in  Table  1.  There  were  no  signiﬁcant  differences  in
ge,  pulse  pressure,  BP,  and  BMI  among  the  three  groups.
imilarly,  there  was  no  signiﬁcant  difference  in  the  preva-
ence  of  HOCM  among  the  three  groups.  Plasma  ANP  levels  in
CM  patients  with  chronic  AF  were  signiﬁcantly  higher  than
hose  in  the  other  two  groups.  Plasma  BNP  levels  in  HCM
atients  with  chronic  AF  were  the  highest,  followed  by  HCM
atients  with  paroxysmal  AF,  and  HCM  patients  with  sinus
hythm.
All  of  the  22  HCM  patients  with  chronic  AF  received
ong-term  anticoagulation  with  warfarin.  Of  the  12  HCM
atients  with  paroxysmal  AF,  7  patients  (58%)  received  long-
erm  anticoagulation  with  warfarin.  Five  HCM  patients  with
aroxysmal  AF,  who  did  not  receive  warfarin,  had  pharma-
ological  maintenance  of  sinus  rhythm.
The  biochemical  and  echocardiographic  characteristics
f  the  three  groups  are  presented  in  Table  2.  The  HOMA  index
n  HCM  patients  with  chronic  AF  was  signiﬁcantly  higher  than
hat  in  HCM  patients  with  sinus  rhythm.  In  addition,  the
revalence  of  insulin  resistance  in  HCM  patients  with  chronic
F  or  with  paroxysmal  AF  was  signiﬁcantly  higher  than  that
n  HCM  patients  with  sinus  rhythm.  There  were  no  signiﬁ-
ant  differences  in  LDL-C,  HDL-C,  and  TG  among  the  three
roups.
LA  dimension  and  the  E/e′ ratio  in  HCM  patients  with
hronic  AF  were  signiﬁcantly  higher  than  those  in  HCM
atients  with  sinus  rhythm.  There  were  no  signiﬁcant  dif-
erences  in  LV  pressure  gradient  and  maximum  LV  thickness
mong  the  three  groups.  Similarly,  there  were  no  signif-
cant  differences  in  EDV,  ESV,  and  EF  among  the  three
roups  of  patients  with  HCM.  Moreover,  moderate  to  severe
itral  regurgitation  was  presented  in  only  a  minority  of  HCM
atients.  There  was  no  signiﬁcant  difference  in  the  preva-
ence  of  moderate  to  severe  mitral  regurgitation  among  the
hree  groups.
In  univariate  logistic  regression  analyses,  insulin  resis-
ance,  increased  LA  size,  and  impaired  LV  diastolic  function
ere  signiﬁcant  determinants  of  AF  (Table  3).  In  multivariate
ogistic  regression  analysis,  increased  LA  size  and  impaired
V  diastolic  function  were  signiﬁcant  determinants  of  AF,
ndependent  of  insulin  resistance.  As  shown  in  Table  4,  the
OMA  index,  the  E/e′ ratio,  EDV,  ESV,  and  EF  were  signiﬁ-
antly  correlated  with  LA  dimension.  In  multiple  regression
nalysis,  the  strongest  determinant  of  LA  dimension  was
he  HOMA  index  (p  =  0.0005),  independent  of  the  E/e′ ratio,
DV,  ESV,  and  EF.  Similarly,  the  HOMA  index,  natriuretic  pep-
ides,  and  LA  dimension  were  signiﬁcantly  correlated  with
he  E/e′ ratio,  as  shown  in  Table  5.  In  multiple  regres-
ion  analysis,  the  HOMA  index  (p  =  0.0019)  and  plasma  BNP
evel  (p  =  0.0001)  were  independent  determinants  of  the
/e′ ratio.
iscussiont  is  widely  acknowledged  that  insulin  resistance  is  a  pre-
ier  risk  factor  for  cardiovascular  disease  [27]  and  this
ssociation  is  partly  mediated  by  its  effect  on  cardiac  struc-
ure  [28]. Consequently,  we  have  examined  the  relations  of
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Table  1  Clinical  characteristics,  natriuretic  peptides,  and  medical  treatments  in  patients  with  HCM.
HCM  with  sinus
rhythm  (n  =  54)
HCM  with  chronic
AF  (n  =  22)
HCM  with  paroxysmal
AF  (n  =  12)
Age,  years  64  ±  12  68  ±  9  63  ±  12
Pulse rate,  beats/min  70  ±  15  68  ±  10  72  ±  12
BP, mmHg
Systole 129  ±  17  135  ±  18  136  ±  16
Diastole 72  ±  12 77  ±  12 80  ±  14
BMI, kg/m2 24.1  ±  2.7  23.6  ±  3.0  25.7  ±  2.5
HOCM, n  (%) 13  (24) 5  (22) 4  (33)
Plasma ANP  level,  pg/mL  38  ±  32  109  ±  102† 58  ±  54
Plasma BNP  level,  pg/mL  146  ±  169  500  ±  447† 180  ±  151*
Medical  treatments,  n  (%)
Warfarin 1  (2)  22  (100)  7  (58)
Calcium antagonists  32  (59)  15  (68)  10  (83)
-Blockers  33  (61)  12  (55)  7  (58)
Class Ia  antiarrhythmic  drugs  15  (28)  6  (27)  4  (33)
Vales are mean ± SD. HCM, hypertrophic cardiomyopathy; HOCM, hypertrophic obstructive cardiomyopathy; AF, atrial ﬁbrillation; BP,
blood pressure; BMI, body mass index; ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide.
* p < 0.01 vs. HCM with chronic AF.
t
i† p < 0.0001 vs. HCM with sinus rhythm.
insulin  resistance  (assessed  by  the  HOMA  index)  to  LV  pres-
sure  gradients  and  sudden  death  in  patients  with  HCM  [13].
The  present  study  added  to  our  previous  study  [13]  by  iden-
tifying  the  signiﬁcant  and  independent  relations  of  insulin
resistance  to  echocardiograhically  determined  LA  size  and  LV
diastolic  function.  Furthermore,  impaired  LV  diastolic  func-
(
m
s
Table  2  Biochemical  and  echocardiographic  characteristics  in  pa
HCM  with  sinus
rhythm  (n  =  54)
Biochemical  parameters
FPG,  mmol/L  5.6  ±  0.9  
FIRI, pmol/L  60.3  ±  27.3  
HOMA index  2.1  ±  0.9  
Insulin resistance,  n  (%)  11  (20)  
LDL-C,  mmol/L  2.87  ±  0.72  
HDL-C, mmol/L  1.51  ±  0.47  
Triglycerides,  mmol/L  1.43  ±  0.58  
Echocardiographic  parameters
LA  dimension,  mm  42.0  ±  6.4  
E/e′ ratio  14.9  ±  4.9  
LVPG, mmHg  20.7  ±  31.4  
Maximum LVT,  mm  16.6  ±  4.1  
EDV, mL  68.6  ±  21.0  
ESV, mL 23.1  ±  11.9  
EF, %  67.3  ±  10.5  
Moderate to  severe  MR,  n  (%) 6  (11)  
Vales are mean ± SD. HCM, hypertrophic cardiomyopathy; AF, atrial ﬁbril
insulin; HOMA, homeostasis model assessment; LDL-C, low-density lipo
LA, left atrial; LVPG, left ventricular pressure gradient; LVT, left ven
volume; EF, ejection fraction; MR, mitral regurgitation.
* p < 0.05 vs. HCM with sinus rhythm.
† p < 0.01 vs. HCM with sinus rhythm.ion  and  increased  LA  size  are  important  determinants  of  AF
n  patients  with  HCM.
Not  only  insulin,  but  also  insulin-like  growth  factor-1
IGF-1),  is  important  in  hypertrophic  response  of  cardiac
yocytes,  by  binding  to  the  IGF-1  receptors  because  of  the
tructural  similarity  between  insulin  and  IGF-1  [28,29]. Mar-
tients  with  HCM.
HCM  with  chronic
AF  (n  =  22)
HCM  with  paroxysmal
AF  (n  =  12)
5.7  ±  0.8  5.3  ±  1.1
84.7  ±  48.8  84.7  ±  61.0
3.1  ±  1.9† 2.7  ±  1.5
10  (45)* 6  (50)*
3.05  ±  0.55  3.08  ±  0.50
1.23  ±  0.22  1.32  ±  0.33
1.34  ±  0.51  1.66  ±  0.76
51.2  ±  10.9† 46.1  ±  8.4
23.6  ±  11.7† 19.7  ±  6.4
18.7  ±  26.5  43.6  ±  61.4
15.7  ±  2.9  16.1  ±  3.5
76.6  ±  25.7  77.6  ±  26.7
29.6  ±  14.3  27.8  ±  17.4
61.8  ±  11.1  66.2  ±  12.4
5  (23)  2  (17)
lation; FPG, fasting plasma glucose; FIRI, fasting immuno-reactive
protein-cholesterol; HDL-C, high-density lipoprotein-cholesterol;
tricular thickness; EDV, end diastolic volume; ESV, end systolic
22  Y.  Shigematsu  et  al.
Table  3  Determinants  of  AF  in  patients  with  HCM.
Variables Univariate  analysis  Multivariate  analysis
OR  (95%  CI)  p-Value  OR  (95%  CI)  p-Value
Age  ≥  60  years  old 1.0  (0.4—2.6)  0.92  NI
Male sex 0.4  (0.1—1.2) 0.39  NI
Obesity (BMI  ≥  25  kg/m2)  1.9  (0.8—4.6) 0.17  NI
Insulin resistance  (HOMA  index  ≥  2.7) 3.5  (1.4—8.9) 0.0097  2.3  (0.8—7.0)  0.12
Increased LA  size  (LA  dimension  ≥  45  mm)  5.7  (2.2—14.6)  0.0003  3.5  (1.2—9.8)  0.018
Impaired LV  diastolic  function  (E/e′ ratio  ≥  18.0)  6.9  (2.6—17.8)  <0.0001  4.6  (1.6—12.8)  0.0037
Maximum LV  thickness  ≥  20  mm  1.0  (0.3—3.3)  0.99  NI
LV outﬂow  obstruction  (gradient  ≥  30  mmHg)  0.8  (0.3—2.3)  0.70  NI
Moderate to  severe  MR  2.1  (0.6—6.8)  0.23  NI
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sNI indicates not included in multivariate analysis. AF, atrial ﬁbrill
diomyopathy; BMI, body mass index; HOMA, homeostasis model as
an  [30]  reported  the  possibility  that  IGF-1  was  up-regulated
n  patients  with  HCM  due  to  decreased  cardiac  contractility,
esulting  in  the  pathologic  manifestations  of  HCM.  Despite
he  structural  similarity  to  IGF-1,  the  relationship  between
nsulin  and  HCM,  which  is  another  cause  of  LV  hypertro-
hy  and  diastolic  dysfunction,  is  incompletely  understood.
ur  previous  study  [13]  disclosed  that  interventricular  sep-
al  thickness  and  LV  pressure  gradient  without  provocation
ere  signiﬁcantly  associated  with  the  HOMA  index,  and  that
hese  associations  were  independent  of  age,  sex  distribu-
ion,  and  blood  pressure  in  patients  with  HCM.  In  the  present
tudy,  we  have  chosen  this  simple  HOMA  index  and  have
ound  that  insulin  resistance  is  highly  prevalent  (31%)  among
on-diabetic  patients  with  HCM.  Insulin  resistance  has  been
ssociated  with  chronic  heart  failure  independently  of  its
tiology  [9,10]. Exact  mechanisms  for  the  development  of
nsulin  resistance  in  chronic  heart  failure  are  not  known.  A
umber  of  mechanisms  have  been  proposed,  including  the
oss  of  skeletal  muscle  bulk  and  skeletal  blood  ﬂow,  sym-
t
I
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Table  4  Correlation  of  LA  size  with  natriuretic  peptides,  demogr
Variables  Univariate  analysis  
r-Value p-Value  
Age 0.028  0.7968  
BMI 0.125  0.2449  
HOMA index 0.431  <0.0001  
Systolic BP 0.055  0.6100  
Diastolic  BP 0.061  0.5709  
Plasma ANP  level 0.161  0.1333  
Plasma BNP  level  0.200  0.0615  
E/e′ ratio  0.316  0.0027  
LV pressure  gradient  0.048  0.6599  
Maximum  LV  thickness  0.001  0.9957  
EDV 0.347  0.0009  
ESV 0.340  0.0012  
EF 0.227  0.0331  
NI indicates not included in multivariate analysis. LA, left atrial; HC
homeostasis model assessment; BP, blood pressure; ANP, atrial natriur
EDV, end diastolic volume; ESV, end systolic volume; EF, ejection fract; OR, odds ratio; CI, conﬁdence interval; HCM, hypertrophic car-
ent; LA, left atrial; LV, left ventricular; MR, mitral regurgitation.
athetic  overactivity,  pro-inﬂammatory  cytokines,  altered
diponectin  and  leptin  levels,  and  endothelial  dysfunction
31].
We  found  in  the  present  study  that  greater  HOMA  index
as  strongly  associated  with  echocardiographic  LA  size  in
atients  with  HCM,  concordant  with  the  ﬁndings  in  our  previ-
us  study  [22]  which  took  hypertensive  patients  as  objects.
n  addition,  it  has  been  shown  that  increased  LA  size  and
A  dysfunction  are  risks  for  AF  [32,33], these  observations
upport  that  higher  insulin  resistance  in  patients  with  HCM
s  related  largely  to  the  development  of  AF.  Furthermore,
t  has  been  reported  that  metabolic  syndrome  is  associ-
ted  with  increased  LA  size  in  patients  with  non-valvular
F  [34]. Another  possible  mechanism  by  which  insulin  resis-
ance  may  predispose  to  AF  is  inﬂammation  and  oxidative
tress.  Although  not  measured  in  our  study,  C-reactive  pro-
ein  and  oxidants  were  elevated  in  patients  with  AF  [35,36].
nsulin  resistance  is  also  associated  with  a  systemic  chronic
nﬂammatory  response  characterized  by  altered  cytokine
aphic  and  echocardiographic  variables  in  patients  with  HCM.
Multivariate  analysis
ˇ  p-Value
NI
NI
0.358  0.0005
NI
NI
NI
NI
0.150  0.1490
NI
NI
0.190  0.5447
0.190  0.5447
−0.128  0.6938
Multiple  R2 =  0.323,  p  <  0.0001
M, hypertrophic cardiomyopathy; BMI, body mass index; HOMA,
etic peptide; BNP, brain natriuretic peptide; LV, left ventricular;
ion.
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Table  5  Correlation  of  the  E/e′ ratio  with  natriuretic  peptides,  demographic  and  echocardiographic  variables  in  patients  with
HCM.
Variables  Univariate  analysis  Multivariate  analysis
r-Value  p-Value  ˇ  p-Value
Age 0.143  0.1837  NI
BMI 0.087  0.4184  NI
HOMA index 0.387  0.0002  0.309 0.0019
Systolic BP 0.149  0.1668  NI
Diastolic  BP 0.128  0.2329  NI
Plasma ANP  level  0.325  0.0020  −0.201  0.2036
Plasma BNP  level  0.465  <0.0001  0.631  0.0001
LA dimension  0.316  0.0027  0.102  0.2895
LV pressure  gradient 0.094  0.3817  NI
Maximum  LV  thickness  0.008  0.9423  NI
EDV 0.181  0.0911  NI
ESV 0.024  0.8255  NI
EF 0.069  0.5236  NI
Multiple  R2 =  0.430,  p  <  0.0001
NI indicates not included in multivariate analysis. HCM, hypertrophic cardiomyopathy; BMI, body mass index; HOMA, homeostasis model
assessment; BP, blood pressure; ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; LA, left atrial; LV, left ventricular; EDV,
on.
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Rend diastolic volume; ESV, end systolic volume; EF, ejection fracti
production  and  activation  of  inﬂammatory  signaling  pathway
[37].
A  relation  between  systolic  blood  pressure  and  LA  size
has  previously  been  reported  in  the  Framingham  Heart  Study
[38].  Our  previous  study  [22]  has  shown  that  obesity  is  highly
associated  with  increased  LA  size.  Unfortunately,  systolic
blood  pressure,  pulse  pressure,  and  body  mass  index  were
not  identiﬁed  as  independent  determinants  of  LA  size  in
patients  with  HCM.  Therefore,  a  mechanistic  link  between
blood  pressure  or  obesity  and  LA  size  is  unclear  in  patients
with  HCM.
HCM  is  functionally  characterized  by  normal  or  supernor-
mal  LV  systolic  function  and  impaired  LV  diastolic  function,
and  the  severity  of  LV  diastolic  dysfunction  is  related  to
exercise  capacity,  clinical  symptoms,  and  even  prognosis
[11,12,39].  Although  transmitral  LV  ﬁlling  velocity  values
recorded  by  Doppler  echocardiography  are  widely  used  to
assess  LV  diastolic  function,  conventional  Doppler  indices
and  the  severity  of  LV  hypertrophy,  exercise  capacity,  clin-
ical  symptoms,  or  the  mean  LA  pressure  were  not  related
in  patients  with  HCM  [40]. The  ratio  of  trasmitral  early
LV  ﬁlling  velocity  to  early  diastolic  Doppler  tissue  imag-
ing  velocity  of  the  mitral  annulus  (E/e′)  has  recently  been
reported  to  be  a  preload  independent  index  for  evaluating
LV  diastolic  function  [41]  and  predicting  objective  exercise
capacity  [42]  in  patients  with  HCM.  In  the  present  study,  the
E/e′ ratio  was  an  independent  association  with  the  devel-
opment  of  AF.  Mechanical  and  pressure  stress  in  the  left
atrium  may  stretch  the  atrial  wall  around  the  pulmonary
veins,  which  may  trigger  the  onset  of  paroxysmal  AF  [43]. In
addition,  the  association  between  the  HOMA  index  and  the
E/e′ ratio  seen  in  this  study  was  independent  of  the  param-
eters  of  LV  hemodynamics  and  structure,  suggested  that
direct,  hemodynamic-independent  effects  of  insulin  resis-
tance  on  myocardium  might  play  a  signiﬁcant  role  for  the
development  of  LV  diastolic  impairment  in  HCM.We also  found  that  higher  plasma  BNP  levels  predicted
he  presence  of  HCM  and  AF,  even  after  accounting  for
ystolic  impairment.  Furthermore,  plasma  BNP  levels  were
ndependently  associated  with  impaired  LV  diastolic  func-
ion  evaluated  by  the  E/e′ ratio  in  HCM.  These  observations
lso  support  that  although  LV  systolic  function  is  normal,
lasma  BNP  levels  are  elevated  in  the  presence  of  impaired
V  diastolic  function  [44,45].
In  conclusion,  insulin  resistance  is  highly  prevalent  among
on-diabetic  patients  with  HCM.  A  possible  mechanism  by
hich  insulin  resistance  affects  the  development  of  AF  is
ediated  through  its  association  with  increased  LA  size  or
V  diastolic  impairment.  Insulin  resistance  may  be  the  under-
ying  mechanism  for  the  higher  prevalence  of  AF  in  HCM.
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